US › Healthcare

Phio Pharmaceuticals Corp (PHIO)

US · Healthcare · Biotechnology

$1.02+2.09%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-4.1M

EPS

$-0.36

EPS estimate

$-0.36

EPS came in at -0.36 against a street estimate of -0.36 — a beat of 0.0%.

Key statistics

Market cap

$11.8M

Forward P/E

0.3

P/B

0.95

Book value

$1.08

EPS (TTM)

$-1.27

52-week high

$2.56

52-week low

$0.81

50-day MA

$1.07

200-day MA

$1.12

Beta

0.80

Analyst view

Analysts rate Phio Pharmaceuticals Corp a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $14.00.

Shareholding

Insiders

3.94%

Institutions

10.21%

Largest institutional holders

Fund	Stake
Geode Capital Management, LLC	1.27%
Jane Street Group LLC	1.03%
Vanguard Capital Management, LLC	0.69%
Cetera Investment Advisers	0.39%
Vanguard Fiduciary Trust Co	0.33%
HRT FINANCIAL LLC	0.30%
Two Sigma Investments LLC	0.28%
Scientech Research LLC	0.26%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Phio Pharmaceuticals Corp — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.